MapLight Therapeutics Shares Climb After Phase 2 IRIS Topline; Subgroup Signals Highlighted
MapLight Therapeutics shares rose 5.7% in morning trading after the company published topline results from its Phase 2 IRIS study of ML-004 in autism spectrum disorder. While the trial did not meet its primary endpoint for social communication deficits, a prespecified subgroup of adolescents with moderate to severe baseline irritability showed mean…